US · Healthcare · Biotechnology
EPS came in at -0.81 against a street estimate of -0.74 — a miss of 9.5%.
Analysts rate Pharvaris BV a strong buy (13 buy, 1 hold, 0 sell out of 14) with an average price target of $57.52.
| Fund | Stake |
|---|---|
| FMR Inc | 9.35% |
| General Atlantic Llc | 9.33% |
| Foresite Capital Management IV, LLC | 6.81% |
| venBio Partners LLC | 6.61% |
| Viking Global Investors LP | 5.20% |
| EQT Fund Management S.à r.l. | 4.88% |
| Deerfield Management Co | 4.81% |
| Bain Capital Life Sciences Investors, LLC | 3.81% |
| Document | Date |
|---|---|
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Pharvaris reported positive topline Phase 3 CHAPTER-3 results for deucrictibant extended-release (XR) 40 mg once daily in heredita | 2026-09-08 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Pharvaris reported positive topline results from the CHAPTER-3 pivotal Phase 3 study of deucrictibant XR for preventing hereditary | 2026-09-08 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Pharvaris reported a net loss of €87,043,402 for the six months ended June 30, 2026, compared with €91,821,509 in the same period | 2026-08-12 |
| Current report (6-K) · Q2 2026 OTHER NOTABLE POINTS • Pharvaris N.V. held its Annual General Meeting of Shareholders on June 26, 2026. • Shareholders adopted the Dutch statutory a | 2026-06-26 |
| Quarterly results (6-K) · Q1 2026 HEADLINE NUMBERS • Pharvaris reported a Q1 2026 net loss of €39,200,673, compared with €46,340,823 in Q1 2025. • Basic and diluted loss per share im | 2026-05-12 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Fiscal year ended December 31, 2025; report prepared under IFRS Accounting Standards in euros. • Pharvaris had 65,210,590 common | 2026-04-02 |
| Quarterly results (6-K) · Q1 2026 HEADLINE NUMBERS • Pharvaris reported a full-year 2025 loss of €175.7 million, or €2.97 per basic and diluted share, compared with a €134.2 million l | 2026-04-02 |
| Quarterly results (6-K) · Q3 2025 HEADLINE NUMBERS • Pharvaris reported a nine-month 2025 net loss of €128,958,544, compared with €99,460,587 in the same period of 2024. • Basic and | 2025-11-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pharvaris BV — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.